Effective treatment of orthostatic tremor with gabapentin.
Identifieur interne : 004351 ( PubMed/Corpus ); précédent : 004350; suivant : 004352Effective treatment of orthostatic tremor with gabapentin.
Auteurs : V G Evidente ; C H Adler ; J N Caviness ; K A GwinnSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1998.
English descriptors
- KwdEn :
- Acetates (administration & dosage), Acetates (adverse effects), Aged, Amines, Anticonvulsants (administration & dosage), Anticonvulsants (adverse effects), Cyclohexanecarboxylic Acids, Dose-Response Relationship, Drug, Drug Administration Schedule, Electromyography (drug effects), Female, Follow-Up Studies, Humans, Isometric Contraction (drug effects), Male, Middle Aged, Postural Balance (drug effects), Posture, Tremor (drug therapy), Weight-Bearing, gamma-Aminobutyric Acid.
- MESH :
- chemical , administration & dosage : Acetates, Anticonvulsants.
- chemical , adverse effects : Acetates, Anticonvulsants.
- drug effects : Electromyography, Isometric Contraction, Postural Balance.
- drug therapy : Tremor.
- Aged, Amines, Cyclohexanecarboxylic Acids, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Male, Middle Aged, Posture, Weight-Bearing, gamma-Aminobutyric Acid.
Abstract
We report seven patients with orthostatic tremor (OT) who were successfully treated with the anticonvulsant gabapentin. Five of the patients had been previously tried on clonazepam, the most commonly used drug for OT, four without any benefit. The degree of improvement perceived by the patients with gabapentin varied from 60-80% (mean 73%). The effective dose of gabapentin ranged from 300-1800 mg/day (mean 1030 mg/day). The side effects were generally mild, transient, and dose-related. Duration of response has so far ranged from 2-22 months (mean 11 months) with all patients still currently benefiting from gabapentin. We conclude that gabapentin may be an effective treatment for OT. Further trials are indicated.
DOI: 10.1002/mds.870130513
PubMed: 9756154
Links to Exploration step
pubmed:9756154Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effective treatment of orthostatic tremor with gabapentin.</title><author><name sortKey="Evidente, V G" sort="Evidente, V G" uniqKey="Evidente V" first="V G" last="Evidente">V G Evidente</name><affiliation><nlm:affiliation>Parkinson's Disease and Movement Disorders Center, Mayo Clinic Scottsdale, Arizona 85259, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Adler, C H" sort="Adler, C H" uniqKey="Adler C" first="C H" last="Adler">C H Adler</name></author><author><name sortKey="Caviness, J N" sort="Caviness, J N" uniqKey="Caviness J" first="J N" last="Caviness">J N Caviness</name></author><author><name sortKey="Gwinn, K A" sort="Gwinn, K A" uniqKey="Gwinn K" first="K A" last="Gwinn">K A Gwinn</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1998">1998</date><idno type="RBID">pubmed:9756154</idno><idno type="pmid">9756154</idno><idno type="doi">10.1002/mds.870130513</idno><idno type="wicri:Area/PubMed/Corpus">004351</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effective treatment of orthostatic tremor with gabapentin.</title><author><name sortKey="Evidente, V G" sort="Evidente, V G" uniqKey="Evidente V" first="V G" last="Evidente">V G Evidente</name><affiliation><nlm:affiliation>Parkinson's Disease and Movement Disorders Center, Mayo Clinic Scottsdale, Arizona 85259, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Adler, C H" sort="Adler, C H" uniqKey="Adler C" first="C H" last="Adler">C H Adler</name></author><author><name sortKey="Caviness, J N" sort="Caviness, J N" uniqKey="Caviness J" first="J N" last="Caviness">J N Caviness</name></author><author><name sortKey="Gwinn, K A" sort="Gwinn, K A" uniqKey="Gwinn K" first="K A" last="Gwinn">K A Gwinn</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1998" type="published">1998</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acetates (administration & dosage)</term><term>Acetates (adverse effects)</term><term>Aged</term><term>Amines</term><term>Anticonvulsants (administration & dosage)</term><term>Anticonvulsants (adverse effects)</term><term>Cyclohexanecarboxylic Acids</term><term>Dose-Response Relationship, Drug</term><term>Drug Administration Schedule</term><term>Electromyography (drug effects)</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Isometric Contraction (drug effects)</term><term>Male</term><term>Middle Aged</term><term>Postural Balance (drug effects)</term><term>Posture</term><term>Tremor (drug therapy)</term><term>Weight-Bearing</term><term>gamma-Aminobutyric Acid</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Acetates</term><term>Anticonvulsants</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Acetates</term><term>Anticonvulsants</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Electromyography</term><term>Isometric Contraction</term><term>Postural Balance</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Tremor</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Amines</term><term>Cyclohexanecarboxylic Acids</term><term>Dose-Response Relationship, Drug</term><term>Drug Administration Schedule</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Posture</term><term>Weight-Bearing</term><term>gamma-Aminobutyric Acid</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We report seven patients with orthostatic tremor (OT) who were successfully treated with the anticonvulsant gabapentin. Five of the patients had been previously tried on clonazepam, the most commonly used drug for OT, four without any benefit. The degree of improvement perceived by the patients with gabapentin varied from 60-80% (mean 73%). The effective dose of gabapentin ranged from 300-1800 mg/day (mean 1030 mg/day). The side effects were generally mild, transient, and dose-related. Duration of response has so far ranged from 2-22 months (mean 11 months) with all patients still currently benefiting from gabapentin. We conclude that gabapentin may be an effective treatment for OT. Further trials are indicated.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">9756154</PMID><DateCreated><Year>1999</Year><Month>01</Month><Day>05</Day></DateCreated><DateCompleted><Year>1999</Year><Month>01</Month><Day>05</Day></DateCompleted><DateRevised><Year>2013</Year><Month>06</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>5</Issue><PubDate><Year>1998</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Effective treatment of orthostatic tremor with gabapentin.</ArticleTitle><Pagination><MedlinePgn>829-31</MedlinePgn></Pagination><Abstract><AbstractText>We report seven patients with orthostatic tremor (OT) who were successfully treated with the anticonvulsant gabapentin. Five of the patients had been previously tried on clonazepam, the most commonly used drug for OT, four without any benefit. The degree of improvement perceived by the patients with gabapentin varied from 60-80% (mean 73%). The effective dose of gabapentin ranged from 300-1800 mg/day (mean 1030 mg/day). The side effects were generally mild, transient, and dose-related. Duration of response has so far ranged from 2-22 months (mean 11 months) with all patients still currently benefiting from gabapentin. We conclude that gabapentin may be an effective treatment for OT. Further trials are indicated.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Evidente</LastName><ForeName>V G</ForeName><Initials>VG</Initials><AffiliationInfo><Affiliation>Parkinson's Disease and Movement Disorders Center, Mayo Clinic Scottsdale, Arizona 85259, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adler</LastName><ForeName>C H</ForeName><Initials>CH</Initials></Author><Author ValidYN="Y"><LastName>Caviness</LastName><ForeName>J N</ForeName><Initials>JN</Initials></Author><Author ValidYN="Y"><LastName>Gwinn</LastName><ForeName>K A</ForeName><Initials>KA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000085">Acetates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000588">Amines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003509">Cyclohexanecarboxylic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>56-12-2</RegistryNumber><NameOfSubstance UI="D005680">gamma-Aminobutyric Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>6CW7F3G59X</RegistryNumber><NameOfSubstance UI="C040029">gabapentin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CitationSubset>S</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000085">Acetates</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D000588">Amines</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000927">Anticonvulsants</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D003509">Cyclohexanecarboxylic Acids</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004334">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004576">Electromyography</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007537">Isometric Contraction</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004856">Postural Balance</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D011187">Posture</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014202">Tremor</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016474">Weight-Bearing</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D005680">gamma-Aminobutyric Acid</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1998</Year><Month>10</Month><Day>2</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1998</Year><Month>10</Month><Day>2</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9756154</ArticleId><ArticleId IdType="doi">10.1002/mds.870130513</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004351 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 004351 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:9756154
|texte= Effective treatment of orthostatic tremor with gabapentin.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:9756154" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |